Editors' Desk

  1. The Generic And Biosimilar Markets: Are They Really That Different? 10/19/2015

    As the FDA continues to compose guidances on the labeling and interchangeability of biosimilar medicines, there remains one big, overarching concern in the industry, and that is making sure biosimilar medicines are not treated as small molecule generics. But should we really be considering the two types of drugs as drastically different as we have been over the past few months?

  2. The Evolution Of A Cold Chain Conference 9/28/2015

    The Cold Chain Global Forum has grown from a niche conference to the life science industry's leading temperature-controlled event.

  3. Performance-Based Pricing Poised To Hit Pharma 9/25/2015

    Many call for transparency to combat high drug costs, but outcomes-based pricing is a more realistic solution.  

  4. FBI Insights On Counterfeit Drug Prevention 9/18/2015

    A former FBI agent shares his tips for protecting your products from counterfeit activity.

  5. Key Trends, Cross Pollination Drive Pharma EXPO 9/15/2015

    Pharma EXPO is right around the corner. Discover the key industry trends that directly influenced this year’s conference program and how the event provides a unique opportunity for pharmaceutical professionals to learn from other industries.

  6. Pharma Needs A Medication Adherence Game Plan 9/14/2015

    Medication nonadherence is a disturbing trend that has a negative effect on patient wellness, hospital costs, and pharmaceutical manufacturer revenue. Drugmakers need to drive improvements in this area and big data, sensor technology, and a new approach to marketing can help.

  7. Keeping Current With The Cold Chain 9/11/2015

    Meeting the temperature-control needs today’s life science products requires manufacturers to balance regulatory compliance with quality and cost. Discover how the 13th Annual Cold Chain Global Forum can provide you with the insight necessary to succeed.

  8. 3 Can't-Miss Sessions At Pharma EXPO 2015 9/3/2015

    Pharma EXPO 2015 offers several educational opportunities to choose from, but these three sessions alone could be worth the trip to Vegas.

  9. Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market? 9/1/2015

    Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?

  10. Shaping The Emerging Biosimilars Landscape 8/26/2015

    The emergence of biosimilars in the U.S. will  undoubtedly have a marked impact on the pharmaceutical industry, but the market is young and malleable. Pharmaceutical manufacturers currently have a unique opportunity to shape perceptions and use of biosimilars among healthcare providers and their patients.